Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Anaptysbio Inc
(NQ:
ANAB
)
21.31
-0.18 (-0.84%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Anaptysbio Inc
< Previous
1
2
3
Next >
12 Health Care Stocks Moving In Friday's Intraday Session
January 06, 2023
Via
Benzinga
Greenbrier, Fate Therapeutics, AnaptysBio And Some Other Big Stocks Moving Lower On Friday
January 06, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 500 points on Friday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 05, 2023
Via
Benzinga
Expert Ratings for AnaptysBio
November 09, 2022
Over the past 3 months, 4 analysts have published their opinion on AnaptysBio (NASDAQ:ANAB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial
October 05, 2022
Via
Benzinga
HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround
September 19, 2022
Via
Benzinga
AnaptysBio Sells Royalty Interest In Cancer Drug For $45M
September 12, 2022
Via
Benzinga
Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback
September 02, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
January 06, 2023
Via
Benzinga
Short Volatility Alert: AnaptysBio, Inc.
May 26, 2022
On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment...
Via
Benzinga
AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers
April 28, 2022
Via
Benzinga
Recap: AnaptysBio Q4 Earnings
March 07, 2022
AnaptysBio (NASDAQ:ANAB) reported its Q4 earnings results on Monday, March 7, 2022 at 09:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
This Analyst Slashes PT On Rent the Runway By Around 43%, Plus JP Morgan Predicts $84 For Oracle
September 13, 2022
Credit Suisse cut the price target for Rent the Runway, Inc. (NASDAQ: RENT) from $7 to $4. Rent the Runway shares fell 30.6% to trade at $3.42 on Tuesday.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022
September 13, 2022
Upgrades See all analyst ratings upgrades.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
September 01, 2022
Upgrades
Via
Benzinga
AnaptysBio Faces Another Setback For Imsidolimab, Stalls Work In Skin Scarring Indication
September 01, 2022
AnaptysBio Inc (NASDAQ: ANAB) announced topline data from its HARP Phase 2 trial of imsidolimab for moderate-to-severe hidradenitis suppurativa (HS).
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 01, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 31, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 07, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
May 27, 2022
During Friday's session, 59 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
June 02, 2022
During the Thursday's session, 100 stocks hit new 52-week lows.
Via
Benzinga
AnaptysBio's Return On Capital Employed Insights
May 24, 2022
Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting in a 11.42% decrease from last quarter.
Via
Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
April 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2022
March 22, 2022
Upgrades For Procter & Gamble Co (NYSE:PG), Truist Securities upgraded the previous rating of Hold to Buy. For the second quarter, Procter & Gamble had an EPS of $1.66,...
Via
Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
March 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne
March 15, 2022
AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne
Via
Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
March 14, 2022
Gainers Sigilon Therapeutics (NASDAQ:SGTX) stock rose 15.5% to $1.49 during Monday's after-market session. The market value of their outstanding shares is at $48.1 million.
Via
Benzinga
AnaptysBio's Return On Capital Employed Insights
March 10, 2022
AnaptysBio (NASDAQ:ANAB) brought in sales totaling $1.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 388.12%, resulting in a loss of...
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.